VYNE Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 0.098 million compared to USD 0.099 million a year ago. Net loss was USD 6.25 million compared to USD 5.62 million a year ago.

Basic loss per share from continuing operations was USD 0.15 compared to USD 1.74 a year ago. Diluted loss per share from continuing operations was USD 0.15 compared to USD 1.74 a year ago. Basic loss per share was USD 0.15 compared to USD 1.74 a year ago.

Diluted loss per share was USD 0.15 compared to USD 1.74 a year ago.